Skip to main content

Lipid Metabolism Disorders

1
Pipeline Programs
4
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
Fluvastatin sodiumPhase 41 trial
Active Trials
NCT01551173Completed436Est. May 2013
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
CoolSculpting® SystemN/A1 trial
Active Trials
NCT04819321Unknown12Est. Mar 2022
Takeda
TakedaTOKYO, Japan
1 program
Natural History Study of Children With Metachromatic LeukodystrophyN/A1 trial
Active Trials
NCT01963650Terminated1Est. Apr 2016
Frontera Therapeutics
Frontera TherapeuticsChina - Suzhou
1 program
Yerba mate consumptionN/A1 trial
Active Trials
NCT06896175Recruiting198Est. Oct 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozFluvastatin sodium
Frontera TherapeuticsYerba mate consumption
AbbVieCoolSculpting® System
TakedaNatural History Study of Children With Metachromatic Leukodystrophy

Clinical Trials (4)

Total enrollment: 647 patients across 4 trials

NCT01551173SandozFluvastatin sodium

Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Start: Jan 2012Est. completion: May 2013436 patients
Phase 4Completed
NCT06896175Frontera TherapeuticsYerba mate consumption

Effect of Ilex Paraguariensis Harvest Time and Consumption Method of Processed Yerba Mate on the Lipid Profile

Start: Feb 2026Est. completion: Oct 2026198 patients
N/ARecruiting
NCT04819321AbbVieCoolSculpting® System

Study of White Adipose Tissue Remodeling by Cryolipolysis in Humans

Start: Apr 2021Est. completion: Mar 202212 patients
N/AUnknown
NCT01963650TakedaNatural History Study of Children With Metachromatic Leukodystrophy

Natural History Study of Children With Metachromatic Leukodystrophy

Start: Nov 2015Est. completion: Apr 20161 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 647 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.